Stay updated on Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.

Latest updates to the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page
- Check2 days agoChange DetectedAdded a system-wide notice about potential data delays due to a lapse in government funding and updated operating status guidance, with references to cc.nih.gov and opm.gov. Updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check9 days agoChange DetectedAdded a glossary display and updated QC-related metadata to show 2025-10-20 Last Update Submitted that Met QC Criteria and Last Update Posted, along with No FEAR Act Data and Revision: v3.4.0. Removed older QC metadata (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data) and the prior Revision: v3.3.4.SummaryDifference0.3%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No substantive changes to study content, layout, or links are evident.SummaryDifference0.0%

- Check45 days agoChange DetectedA consolidated Locations section was added and organized to list study sites in California, Connecticut, Texas, and Washington, with related per-location entries updated accordingly.SummaryDifference0.4%

- Check74 days agoChange DetectedPublications section wording now states that publications are automatically filled from PubMed, and the revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page no longer shows the government funding lapse notice regarding NIH operations. The study details and participation information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.